Hospital burden of pulmonary arterial hypertension in France
Autoři:
Emmanuel Bergot aff001; Lucie De Leotoing aff003; Hakim Bendjenana aff004; Charlène Tournier aff003; Alexandre Vainchtock aff003; Gaëlle Nachbaur aff004; Marc Humbert aff005
Působiště autorů:
Service de Pneumologie & Oncologie Thoracique, Centre Hospitalier Universitaire de Caen, Caen, France
aff001; Unicaen, UFR santé, Caen, France
aff002; HEVA, Lyon, France
aff003; GlaxoSmithKline, Rueil-Malmaison, France
aff004; Université Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin Bicêtre, France
aff005; Assistance Publique Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Le Kremlin Bicêtre, France
aff006; Inserm UMR_S 999, Le Kremlin Bicêtre, France
aff007
Vyšlo v časopise:
PLoS ONE 14(9)
Kategorie:
Research Article
doi:
https://doi.org/10.1371/journal.pone.0221211
Souhrn
Background & aims
Pulmonary arterial hypertension is a severe disease associated with frequent hospitalisations. This retrospective analysis of the French medical information PMSI-MSO database aimed to describe incident cases of patients with pulmonary arterial hypertension hospitalised in France in 2013 and to document associated hospitalisation costs from the national health insurance perspective.
Methods
Cases of pulmonary arterial hypertension were identified using a diagnostic algorithm. All cases hospitalised in 2013 with no hospitalisation the previous two years were retained. All hospital stays during the year following the index hospitalisation were extracted, and classified as incident stays, monitoring stays or stays due to disease worsening. Costs were attributed from French national tariffs.
Results
384 patients in France were hospitalised with incident pulmonary arterial hypertension in 2013. Over the following twelve months, patients made 1,271 stays related to pulmonary arterial hypertension (415 incident stays, 604 monitoring stays and 252 worsening stays). Mean age was 59.6 years and 241 (62.8%) patients were women. Liver disease and connective tissue diseases were documented in 62 patients (16.1%) each. Thirty-one patients (8.1%) died during hospitalisation and four (1.0%) received a lung/heart-lung transplantation. The total annual cost of these hospitalisations was € 3,640,382. € 2,985,936 was attributable to standard tariffs (82.0%), € 463,325 to additional ICU stays (12.7%) and € 191,118 to expensive drugs (5.2%). The mean cost/stay was € 2,864, ranging from € 1,282 for monitoring stays to € 7,285 for worsening stays.
Conclusions
Although pulmonary arterial hypertension is rare, it carries a high economic burden.
Klíčová slova:
Medicine and health sciences – Health care – Health care facilities – Hospitals – Pulmonology – Pulmonary hypertension – Surgical and invasive medical procedures – Minimally invasive surgery – Diagnostic medicine – Cardiovascular anatomy – Blood vessels – Arteries – Pulmonary arteries – Biology and life sciences – Biochemistry – Hormones – Lipid hormones – Prostacyclin – Anatomy – People and places – Geographical locations – Europe – European Union – France
Zdroje
1. Provencher S, Jais X, Yaici A, Sitbon O, Humbert M, Simonneau G. Clinical challenges in pulmonary hypertension: Roger S. Mitchell lecture. Chest. 2005;128(6 Suppl):622s–8s. Epub 2005/12/24. doi: 10.1378/chest.128.6_suppl.622S-a 16373880.
2. Hoeper MM, Simon RGJ. The changing landscape of pulmonary arterial hypertension and implications for patient care. European respiratory review: an official journal of the European Respiratory Society. 2014;23(134):450–7. Epub 2014/12/03. doi: 10.1183/09059180.00007814 25445943.
3. Montani D, Gunther S, Dorfmuller P, Perros F, Girerd B, Garcia G, et al. Pulmonary arterial hypertension. Orphanet journal of rare diseases. 2013;8:97. Epub 2013/07/09. doi: 10.1186/1750-1172-8-97 23829793; PubMed Central PMCID: PMC3750932.
4. Murali S. Pulmonary arterial hypertension. Current opinion in critical care. 2006;12(3):228–34. Epub 2006/05/05. doi: 10.1097/01.ccx.0000224867.78581.0c 16672782
5. Farber HW, Miller DP, Poms AD, Badesch DB, Frost AE, Muros-Le Rouzic E, et al. Five-Year outcomes of patients enrolled in the REVEAL Registry. Chest. 2015;148(4):1043–54. Epub 2015/06/13. doi: 10.1378/chest.15-0300 26066077.
6. McGoon MD, Benza RL, Escribano-Subias P, Jiang X, Miller DP, Peacock AJ, et al. Pulmonary arterial hypertension: epidemiology and registries. Journal of the American College of Cardiology. 2013;62(25 Suppl):D51-9. Epub 2013/12/21. doi: 10.1016/j.jacc.2013.09.017 24355642.
7. Hoeper MM, Humbert M, Souza R, Idrees M, Kawut SM, Sliwa-Hahnle K, et al. A global view of pulmonary hypertension. The Lancet Respiratory medicine. 2016;4(4):306–22. Epub 2016/03/16. doi: 10.1016/S2213-2600(15)00543-3 26975810.
8. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. Pulmonary arterial hypertension in France: results from a national registry. American journal of respiratory and critical care medicine. 2006;173(9):1023–30. Epub 2006/02/04. doi: 10.1164/rccm.200510-1668OC 16456139.
9. Ling Y, Johnson MK, Kiely DG, Condliffe R, Elliot CA, Gibbs JS, et al. Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. American journal of respiratory and critical care medicine. 2012;186(8):790–6. Epub 2012/07/17. doi: 10.1164/rccm.201203-0383OC 22798320.
10. Escribano-Subias P, Del Pozo R, Roman-Broto A, Domingo Morera JA, Lara-Padron A, Elias Hernandez T, et al. Management and outcomes in chronic thromboembolic pulmonary hypertension: From expert centers to a nationwide perspective. International journal of cardiology. 2016;203:938–44. Epub 2015/12/01. doi: 10.1016/j.ijcard.2015.11.039 26618257.
11. Hoeper MM, Huscher D, Pittrow D. Incidence and prevalence of pulmonary arterial hypertension in Germany. International journal of cardiology. 2016;203:612–3. Epub 2015/11/19. doi: 10.1016/j.ijcard.2015.11.001 26580339.
12. Hoeper MM, Huscher D, Ghofrani HA, Delcroix M, Distler O, Schweiger C, et al. Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. International journal of cardiology. 2013;168(2):871–80. Epub 2012/11/21. doi: 10.1016/j.ijcard.2012.10.026 23164592
13. McGoon MD, Miller DP. REVEAL: a contemporary US pulmonary arterial hypertension registry. European respiratory review: an official journal of the European Respiratory Society. 2012;21(123):8–18. Epub 2012/03/02. doi: 10.1183/09059180.00008211 22379169.
14. Burke JP, Hunsche E, Regulier E, Nagao M, Buzinec P, Drake Iii W. Characterizing pulmonary hypertension-related hospitalization costs among Medicare Advantage or commercially insured patients with pulmonary arterial hypertension: a retrospective database study. The American journal of managed care. 2015;21(3 Suppl):s47–58. Epub 2015/03/04. 25734573.
15. Gu S, Hu H, Dong H. Systematic Review of the Economic Burden of Pulmonary Arterial Hypertension. PharmacoEconomics. 2016;34(6):533–50. Epub 2015/12/31. doi: 10.1007/s40273-015-0361-0 26714685.
16. Angalakuditi M, Edgell E, Beardsworth A, Buysman E, Bancroft T. Treatment patterns and resource utilization and costs among patients with pulmonary arterial hypertension in the United States. Journal of medical economics. 2010;13(3):393–402. Epub 2010/07/09. doi: 10.3111/13696998.2010.496694 20608882
17. Johnson S, Delate T, Boka A, Shaw P, Zager C. Characterizing the financial burden of pulmonary arterial hypertension within an integrated healthcare delivery system. Journal of medical economics. 2013;16(12):1414–22. Epub 2013/10/01. doi: 10.3111/13696998.2013.849713 24074226.
18. Kirson NY, Birnbaum HG, Ivanova JI, Waldman T, Joish V, Williamson T. Excess costs associated with patients with pulmonary arterial hypertension in a US privately insured population. Applied health economics and health policy. 2011;9(5):293–303. Epub 2011/08/31. doi: 10.2165/11592430-000000000-00000 21875160.
19. Sikirica M, Iorga SR, Bancroft T, Potash J. The economic burden of pulmonary arterial hypertension (PAH) in the US on payers and patients. BMC health services research. 2014;14:676. Epub 2014/12/30. doi: 10.1186/s12913-014-0676-0 25539602; PubMed Central PMCID: PMC4301626.
20. Bezin J, Duong M, Lassalle R, Droz C, Pariente A, Blin P, et al. The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology. Pharmacoepidemiology and drug safety. 2017;26(8):954–62. Epub 2017/05/26. doi: 10.1002/pds.4233 28544284.
21. World Health Organization. International Classification of Diseases 10th Revision, 4th Edition. Geneva: WHO, 2010.
22. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. The European respiratory journal. 2009;34(6):1219–63. Epub 2009/09/15. doi: 10.1183/09031936.00139009 19749199.
23. Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. Revista espanola de cardiologia (English ed). 2016;69(2):177. Epub 2016/02/04. doi: 10.1016/j.rec.2016.01.002 26837729.
24. Scan Santé. La plateforme de restitution des données des établissements de santé. [Internet]. ATIH. 2017 [cited 20th Novembr 2017]. Available from: http://www.scansante.fr/.
25. Heresi GA, Platt DM, Wang W, Divers CH, Joish VN, Teal SA, et al. Healthcare burden of pulmonary hypertension owing to lung disease and/or hypoxia. BMC pulmonary medicine. 2017;17(1):58. Epub 2017/04/13. doi: 10.1186/s12890-017-0399-1 28399914; PubMed Central PMCID: PMC5387228.
26. Said Q, Martin BC, Joish VN, Kreilick C, Mathai SC. The cost to managed care of managing pulmonary hypertension. Journal of medical economics. 2012;15(3):500–8. Epub 2012/02/09. doi: 10.3111/13696998.2012.665109 22313330.
27. Molinari N, Chanez P, Roche N, Ahmed E, Vachier I, Bourdin A. Rising total costs and mortality rates associated with admissions due to COPD exacerbations. Respiratory research. 2016;17(1):149. Epub 2016/11/16. doi: 10.1186/s12931-016-0469-6 27842545; PubMed Central PMCID: PMC5109821.
28. Bouée S, Laurendeau C, Detournay B, Kind B, Deschaseaux C, Ong SH, et al. Costs of acute heart failure in France. Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2013;16(Suppl):A521.
29. Maladie Assurance. Améliorer la qualité du système de santé et maîtriser les dépenses. Propositions de l’Assurance Maladie pour 2019. Paris: Caisse Nationale de l'Assurance Maladie, 2018.
30. Chevalier P, De Beule J, Lamotte M, Hunsche E, Regulier E. Cost of a Pulmonary Arterial Hypertension-Related Hospitalization in Belgium. Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2014;17(7):A593. Epub 2014/11/01. doi: 10.1016/j.jval.2014.08.2037 27202033.
31. Wilkens H, Grimminger F, Hoeper M, Stahler G, Ehlken B, Plesnila-Frank C, et al. Burden of pulmonary arterial hypertension in Germany. Respiratory medicine. 2010;104(6):902–10. Epub 2010/02/13. doi: 10.1016/j.rmed.2010.01.002 20149617.
Článek vyšel v časopise
PLOS One
2019 Číslo 9
- S diagnostikou Parkinsonovy nemoci může nově pomoci AI nástroj pro hodnocení mrkacího reflexu
- Je libo čepici místo mozkového implantátu?
- Pomůže v budoucnu s triáží na pohotovostech umělá inteligence?
- AI může chirurgům poskytnout cenná data i zpětnou vazbu v reálném čase
- Nová metoda odlišení nádorové tkáně může zpřesnit resekci glioblastomů
Nejčtenější v tomto čísle
- Graviola (Annona muricata) attenuates behavioural alterations and testicular oxidative stress induced by streptozotocin in diabetic rats
- CH(II), a cerebroprotein hydrolysate, exhibits potential neuro-protective effect on Alzheimer’s disease
- Comparison between Aptima Assays (Hologic) and the Allplex STI Essential Assay (Seegene) for the diagnosis of Sexually transmitted infections
- Assessment of glucose-6-phosphate dehydrogenase activity using CareStart G6PD rapid diagnostic test and associated genetic variants in Plasmodium vivax malaria endemic setting in Mauritania
Zvyšte si kvalifikaci online z pohodlí domova
Všechny kurzy